Pakistan, China Sign $850 Million Deals to Boost Pharmaceutical Cooperation

Pakistan and China have signed agreements and memoranda of understanding (MOUs) worth $850 million to bolster cooperation in the pharmaceutical and healthcare sectors. This development marks a significant step towards addressing Pakistan's long-standing reliance on imported medicines and vaccines. The Pakistan-China Pharmaceutical and Healthcare B2B Investment Conference, held in Islamabad from July 17-18, saw participation from 146 Chinese companies with approximately 220 delegates and over 200 Pakistani firms. Discussions covered a wide range of collaborations in vaccine production, active pharmaceutical ingredients (API), medical devices, and clinical trials. Pakistan's dependence on imports is critical, with all 13 vaccines under its national immunization program being imported. Furthermore, while Pakistan manufactures about 85 percent of its finished medicines locally, it imports around 95 percent of the API required for their production. This reliance makes its healthcare system vulnerable to global shipping delays, currency fluctuations, and changes in foreign aid priorities. The recent agreements are expected to facilitate domestic vaccine production capacity building, enhance health security, and reduce the import of medicines and vaccines through Chinese investment and technology transfer. Local production of APIs is also anticipated to lower medicine prices, benefiting the public. Chinese companies are set to establish plants in Pakistan through joint ventures, co-produce raw materials, and build new industrial capacity. Many of these units are expected to be located in special economic zones under the China-Pakistan Economic Corridor (CPEC), where policy incentives are designed to accelerate industrial growth. However, challenges such as regulatory hurdles and other obstacles in research and development may still face Chinese private investors. For the partnership to yield results, the Pakistani government must provide a competitive, transparent environment free from political instability and regulatory confusion. Information source: The Diplomat Indonesia